Cargando…

Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R

BACKGROUND: Uveal melanoma (UM) is the most common primary intraocular tumour of adults, frequently metastasising to the liver. Hepatic metastases are difficult to treat and are mainly unresponsive to chemotherapy. To investigate why UM are so chemo-resistant we explored the effect of interstrand cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gravells, P, Hoh, L, Canovas, D, Rennie, I G, Sisley, K, Bryant, H E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068498/ https://www.ncbi.nlm.nih.gov/pubmed/21386838 http://dx.doi.org/10.1038/bjc.2011.56

Ejemplares similares

Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia
por: Gravells, P, et al.
Publicado: (2013)

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy
por: Wynne, P, et al.
Publicado: (2007)

Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor
por: Jamieson, D, et al.
Publicado: (2006)

Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival
por: Kwakman, R, et al.
Publicado: (2015)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3
por: Patel, S A A, et al.
Publicado: (2014)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines
por: Salawu, Abdulazeez, et al.
Publicado: (2016)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
por: Smith, N F, et al.
Publicado: (2008)

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
por: Martinez, V G, et al.
Publicado: (2008)

The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1
por: Potter, G A, et al.
Publicado: (2002)

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo
por: Armstrong, J L, et al.
Publicado: (2007)

Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model
por: Thies, A, et al.
Publicado: (2008)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

TCTP as a therapeutic target in melanoma treatment
por: Boia-Ferreira, M, et al.
Publicado: (2017)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma
por: Doherty, Rachel E., et al.
Publicado: (2019)

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

Combined effects of GSTP1 and MRP1 in melanoma drug resistance
por: Depeille, P, et al.
Publicado: (2005)

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
por: O'Boyle, G, et al.
Publicado: (2013)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
por: Gammons, M V, et al.
Publicado: (2014)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
por: Ferrucci, P F, et al.
Publicado: (2015)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
por: Azimi, A, et al.
Publicado: (2014)

Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts
por: Eicher, C, et al.
Publicado: (2013)

Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice
por: Thies, A, et al.
Publicado: (2007)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion
por: Siret, Carole, et al.
Publicado: (2015)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
por: Chatelut, E, et al.
Publicado: (2012)

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
por: Gottlieb, D J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_9j8iagbb5ue5o82tgut98tc8rn